Boston Scientific ADVENT trial ‘surprised to the upside,’ says Jefferies

After Boston Scientific announced 12-month results from the ADVENT clinical trial of the Farapulse Pulsed Field Ablation, or PFA, System, that demonstrating the system’s non-inferiority to traditional RF and Cryo ablation approaches on its primary safety and efficacy endpoints in 607 paroxysmal patients with atrial fibrillation, or AF, Jefferies said the trial results “surprised to the upside.” The firm, which views the data as “a key positive” and “a clearing event,” sees the results “making the product highly likely to be approved in ’24,” the analyst tells investors. Jefferies has a Buy rating and $62 price target on Boston Scientific shares.